Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Inventiva Pharma logo — A clinical-stage biopharmaceutical company focused on the de...

Inventiva Pharma

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies.

Founded 2012 France France 108 employees Post-IPO Equity Total: $276.30M Biopharma, Biotechnology +1

General Information

Company Name Inventiva Pharma
Founded Year 2012
Location France France
Employees 108
Industries Biopharma, Biotechnology, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Inventiva Pharma. To contact Inventiva Pharma, visit inventivapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inventiva Pharma compare?

A PDF of Inventiva Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inventiva Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inventiva Pharma

Inventiva Pharma, founded in 2012 and headquartered in France, is a clinical-stage biopharmaceutical company specializing in developing oral small molecule therapies for critical unmet medical needs. Their research targets areas such as fibrosis, lysosomal storage disorders, and oncology, with specific programs focusing on NASH, MPS, and oncology indications.

The company operates within the Biopharma, Biotechnology, and Medical Devices industries, aiming to address significant gaps in current therapeutic offerings. Recent financial backing includes a substantial €115.60M Post-IPO Equity investment from a robust consortium of investors—specifically New Enterprise Associates, Sofinnova Partners, Invus, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Schonfeld Strategic Advisors, Great Point Partners, Eventide, and Biotechnology Value Fund—as of October 14, 2024.

Business keywords: Biopharmaceutical, Clinical-stage, Oral Small Molecule Therapies, Fibrosis, Lysosomal Storage Disorders, Oncology, NASH (Nonalcoholic Steatohepatitis), MPS (Mucopolysaccharidoses), SSc (Systemic Sclerosis), Drug Discovery, Nuclear Receptors, Transcription Factors, Epigenetic Modulation, Proprietary Molecules, Research and Development

Services & Products

Development of oral small molecule therapies
Clinical trials and research programs
Drug candidate development for unmet medical needs

Target Customers

Patients with fibrosis Patients with lysosomal storage disorders Patients with oncology needs Health care providers and researchers focusing on NASH and MPS

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €115.60M 10
New Enterprise Associates Sofinnova Partners Invus
New Enterprise Associates, Sofinnova Partners +8
14 Oct 2024
Post IPO Debt €25.00M 1
European Investment Bank
10 Jan 2024
Post IPO Equity €35.70M 3
Sofinnova Partners
Sofinnova Partners, Yiheng Capital +1
31 Aug 2023
Post IPO Debt €25.00M 1
European Investment Bank
16 May 2022
Post IPO Debt €10.00M -
19 May 2020
Post IPO Equity €15.00M 4
New Enterprise Associates Novo Holdings Sofinnova Partners
New Enterprise Associates, Novo Holdings +2
07 Feb 2020
Grant $3.50M 1
AbbVie
03 Dec 2019
Post IPO Equity €8.20M 3
New Enterprise Associates Novo Holdings
New Enterprise Associates, Novo Holdings +1
30 Sep 2019
Post IPO Equity €36.00M 3
Novo Holdings Sofinnova Partners
Novo Holdings, Sofinnova Partners +1
13 Apr 2018
Grant €2.30M 2
European Commission, Agence National de la Recherche
19 Sep 2016

Inventiva Pharma Alternatives & Competitors

View All Alternatives
Inventiva Pharma vs
GENFIT
GENFIT France

Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical...

Post-IPO Equity
201 employees
Biopharma, Biotechnology
Inventiva Pharma vs
Sling Therapeutics
Sling Therapeutics United States

Focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease...

Series A
12 employees
Biopharma, Biotechnology
Inventiva Pharma vs
VRise Therapeutics, Inc.
VRise Therapeutics, Inc. United States

A Precision Oncology Company

5 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Inventiva Pharma

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies.
Inventiva Pharma was founded in 2012.
Inventiva Pharma is headquartered in France.
Inventiva Pharma operates in Biopharma, Biotechnology and Medical Devices. Its work centres on Biopharmaceutical, Clinical-stage, Oral Small Molecule Therapies and Fibrosis. Its customers include Patients with fibrosis, Patients with lysosomal storage disorders and Patients with oncology needs.
Inventiva Pharma has approximately 108 employees.
Inventiva Pharma has completed 10 funding rounds, raising a total of $276.30M. The latest funding stage is Post-IPO Equity.
Inventiva Pharma offers: Development of oral small molecule therapies, Clinical trials and research programs, Drug candidate development for unmet medical needs.
Top alternatives and competitors to Inventiva Pharma include GENFIT, Sling Therapeutics, VRise Therapeutics, Inc., Ansun Biopharma, Inc., Response Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inventiva Pharma and GENFIT are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inventiva Pharma, https://bouncewatch.com/company/inventiva-pharma, updated 23 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes